EASL 2013: Anemia Is a Common Side Effect of First-generation HCV Protease Inhibitors
- Details
- Category: HCV Treatment
- Published on Wednesday, 15 May 2013 00:00
- Written by Liz Highleyman
About half of patients taking boceprevir (Victrelis) or telaprevir (Incivek or Incivo) developed anemia and approximately one-third experienced skin rash, but sustained response rates were high in an analysis of a population representative of people with chronic hepatitis C in North America, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
Web Design and Development by